Grant Award Details
Immunotherapy for HIV infection using engineered hematopoietic stem/progenitor cells
Grant Application Details
- Immunotherapy for HIV infection using engineered hematopoietic stem/progenitor cells
The therapeutic candidate proposed here is hematopoietic stem/progenitor cells engineered to encode for HIV-specific T cell receptors.
The success of the proposed studies will test the efficacy of an approach to provide long-lasting functional cure for HIV infection, obviating the need for anti-retroviral therapy.
Major Proposed Activities
- Test if engineered hematopoietic stem/progenitor cells can engraft in humanized mice and differentiate into engineered HIV-specific cytotoxic T cells.
- Test if cytotoxic T cells differentiating from engineered hematopoietic stem/progenitor cells are functionally active in vitro.
- Test if engineered hematopoietic stem/progenitor cells can suppress HIV infection in engrafted mice.
HIV affects >200,000 individuals in the State of California. The current anti-HIV treatment needs to be taken constantly for the patient’s life time, is expensive, and has negative side effects. The proposed research can address these issues by using engineered hematopoietic stem cells to treat HIV infection. Success of this approach will lead to clinical trials that will be initiated in California and will lead to therapies that will benefit millions of HIV patients in California and worldwide.
- Nat Methods (2019) T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. (PubMed: 30700902)
- Nat Methods (2019) T cell antigen discovery via trogocytosis. (PubMed: 30700903)